{Reference Type}: Journal Article
{Title}: Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of polycystic ovary syndrome-A systematic review and meta-analysis.
{Author}: Tong X;Song X;Zhang Y;Zhao Q;
{Journal}: Arch Physiol Biochem
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 31
{Factor}: 3.188
{DOI}: 10.1080/13813455.2024.2380422
{Abstract}: <B>UNASSIGNED: </B>Polycystic ovary syndrome (PCOS) is an endocrine gynaecological disorder that affects many women of childbearing age.<BR><B>UNASSIGNED: </B>To evaluate the efficacy and safety of glucose-like peptide-1 receptor agonists for obese women with PCOS.<BR><B>UNASSIGNED: </B>We searched the PubMed, Embase, WOS, and Cochrane Libarary databases up to June 2023. Studies were eligible if they were randomised controlled trials (RCTs) comparing GLP-1RAs against any other treatments for patients with PCOS.<BR><B>UNASSIGNED: </B>Overall, a total of 8 RCTs were included in this review, 7 of the RCTs compared GLP-1RAs with metformin, and 1 RCT compared GLP-1Ras with dapagliflozin. Compared with control group, GLP-1RAs were more effective at improving insulin sensitivity, reducing BMI, and resulting in a smaller waist circumference.<BR><B>UNASSIGNED: </B>GLP-1RAs may be a good option for obese women with PCOS, especially those with insulin resistance. However, high-quality studies are also needed in the future to assess the efficacy of GLP-1RAs in women with PCOS.